ReviewFrontiers in endocrinology2026
The mechanistic role of adipokine imbalance in airway inflammation, hyperresponsiveness, and remodeling in obesity-related asthma.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity-related asthma (OBA) is a clinically important asthma phenotype characterized by poor disease control, increased exacerbation risk, and frequent corticosteroid insensitivity. Although obesity-related mechanical loading contributes to respiratory symptoms, it does not fully explain the inflammatory, functional, and structural features of this phenotype. This review examines adipokine dysregulation, particularly leptin excess and adiponectin insufficiency, as a biologically plausible axis linking systemic metabolic dysfunction to airway-relevant pathology. Epidemiological, animal, and airway-cellular evidence supports adipokine involvement of variable strength in three interconnected domains, including immune amplification through context-dependent macrophage and NLRP3 inflammasome activation, airway hyperresponsiveness (AHR) through inflammatory, neural bronchomotor, and airway smooth muscle (ASM) pathways, and remodeling through epithelial repair failure, ASM proliferation, peribronchial adipose tissue (PBAT) and airway-associated adipose tissue (AAAT) adipose-airway crosstalk, fibroblast activation, and extracellular matrix (ECM) deposition. A spatial-temporal model is proposed in which systemic endocrine adipokine signals may be complemented by local adipose-airway paracrine effects, while persistent metabolic inflammation may shift disease expression from a potentially reversible inflammatory and hyperresponsive state toward remodeling-predominant pathology. Clinically, adipokines are best viewed as candidate stratification markers integrated with metabolic, inflammatory, functional, and structural readouts, and metabolic interventions should be interpreted as phenotype-directed interventions with potential disease-modifying relevance and biomarker endpoints. The translational value of this framework lies in guiding airway-focused validation, longitudinal phenotyping, and mechanistic intervention trials that can distinguish weight-loss effects from direct metabolic-inflammatory airway modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.